HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

EFFICACY OF NICORANDIL IN THE TREATMENT OF PATIENTS WITH CORONARY HEART DISEASE

Download full text PDF
Issue: 
12
Year: 
2017

T. Potupchik(1), Candidate of Medical Sciences; O. Veselova(1), Candidate of Medical Sciences; L. Evert(2, 3), MD; O. Averyanova(4); A. Romanchikov(5) 1-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University 2-Research Institute of Medical Problems of the North, Separate Unit, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences 3-N.F. Katanov Khakass State University, Ministry of Education and Science of the Russian Federation, Abakan 4-Krasnoyarsk Interdistrict Maternity Hospital Four 5-OOO «PIK-FARMA», Moscow

The paper reviews researches on the use the adenosine triphosphate-sensitive potassium channel activator nicorandil in the treatment of coronary heart disease.

Keywords: 
cardiology
nicorandil
exertional angina
quality of life
cardioprotection
prognosis of coronary heart disease



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ageev F.T., Smirnova M.D., Fofanova T.V. Povyshenie priverzhennosti k terapii: «Delo tehniki»? // Serdechnaja nedostatochnost'. – 2011; 12 (4): 66.
  2. Voronina V.P., Martsevich, S.Ju., Kutishenko N.P. i dr. Otsenka antiishemicheskogo i antianginal'nogo effektov nikorandila s pomosch'ju nagruzochnyh testov na tredmile v ramkah issledovanija KVAZAR // RKZh. – 2017; 3: 97–103.
  3. Giljarevskij S.R., Orlov V.A., Seredenina E.M. Samokontrol' i samolechenie bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju: granitsy effektivnosti i bezopasnosti // Serdechnaja nedostatochnost'. – 2002; 3 (5): 237–44.
  4. Giljarevskij S.R., Rezvan V.V., Kuz'mina I.M. i dr. Sovremennye podhody k protivoishemicheskoj terapii bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdtsa // RMZh. – 2014; 12: 928.
  5. Egorov V.A., Shilova E.V., Martsevich S.Ju. Vybor terapii nitratami u bol'nyh stabil'noj stenokardiej naprjazhenija: sravnitel'noe issledovanie obychnyh tabletok izosorbida dinitrata i razlichnyh lekarstvennyh form izosorbida­5mononitrata // Rats. farmakoter. i kardiol. – 2008; 2: 19–22.
  6. Eshihisa A., Sato Ju., Vatanabe S. i dr. Snizhenie smertnosti u bol'nyh s serdechnoj nedostatochnost'ju ishemicheskoj etiologii, prinimajuschih nikorandil // Consilium Medicum. – 2017; 19 (10): 74–8.
  7. Zhiljaev E.V. Nitraty v lechenii stabil'noj stenokardii: novye gorizonty // Sonsilium Medicum. – 2010; 1: 14–8.
  8. Kardiovaskuljarnaja profilaktika. Natsional'nye rekomendatsii. VNOK // Kardiovask. ter. i profilakt. – 2011; 6 (Pril. 2): 57.
  9. Karpov Ju.A., Sorokin E.V.. Stabil'naja ishemicheskaja bolezn' serdtsa: strategija i taktika lechenija. 3-e izd. / M., 2012.
  10. Martsevich, S.Ju., Kutishenko N.P. i dr. Sravnitel'naja otsenka antianginal'noj effektivnosti i bezopasnostipreparata nikorandil na fone bazisnoj terapii β-adrenoblokatorami u bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej // Kardiologija. – 2016; 10: 30–4.
  11. Martsevich S.Ju., Kutishenko N.P., Egorov V.A. i dr. Sravnitel'noe issledovanie effektivnosti i perenosimosti antianginal'nyh preparatov razlichnyh grupp – nitrovazodilatatora (izosorbida-5-mononitrat prolongirovannogo dejstvija) i beta-blokatora s vazodilatirujuschim dejstviem (nebivolol) // Rats. farmakoter. v kardiol. – 2011; 7 (5): 555–60.
  12. Martsevich S.Ju., Navasardjan A.R., Kutishenko N.P. i dr. Otsenka priverzhennosti k priemu novyh oral'nyh antikoaguljantov u patsientov s fibrilljatsiej predserdij po dannym registra profil' // RFK. – 2014; 10 (6): 625–307.
  13. Martsevich S.Ju., Lukina Ju.V., Kutishenko N.P. i dr. Nabljudatel'noe mnogotsentrovoe issledovanie primenenija nikorandila u bol'nyh stabil'noj ishemicheskoj bolezn'ju serdtsa s vysokim serdechno-sosudistym riskom (NIKEJa): dizajn, pervye rezul'taty // Ros. kardiol. zhurn. – 2017; 9 (149): 82–9.
  14. Oganov R.G., Mamedov M.N. Natsional'nye klinicheskie rekomendatsii VNOK / M.: «Silitseja-Poligraf», 2009; 528 s.
  15. Rubrikator klinicheskih rekomendatsij i svjazannyh dokumentov [Elektronnyj resurs] Rossijskoe kardiologicheskoe obschestvo; Natsional'noe obschestvo po izucheniju ateroskleroza; Natsional'noe obschestvo po aterotrombozu. Elektron.dan. / M.: Klinicheskie rekomendatsii. Stabil'naja ishemicheskaja bolezn' serdtsa Rezhim dostupa: http://cr.rosminzdrav.ru/schema.html?id=133#/text
  16. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. i dr. Dopolnitel'nye vozmozhnosti v lechenii ishemicheskoj bolezni serdtsa, oslozhnennoj hronicheskoj serdechnoj nedostatochnost'ju s nizkoj fraktsiej vybrosa levogo zheludochka // Serdechnaja nedostatochnost'. – 2016; 17 (1): 3–9.
  17. Sizova Zh.M., Zaharova V.L., Kozlova N.V. i dr. Vlijanie aktivatora kalievyh kanalov nikorandila na kachestvo zhizni bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej naprjazhenija // Kardiologija. – 2016; 56 (6): 57–62.
  18. Aizawa K., et al. Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation // J. Pharmacol. Sci. – 2015; 127 (3): 284–91.
  19. Eguchi Y., Takahari Y., Higashijima N. et al. Nicorandil Attenuates FeCl3-Induced Thrombus Formation Through the Inhibition of Reactive Oxygen Species Production // Circ. J. – 2009; 73 (3): 554–61.
  20. IONA study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial // Lancet. – 2002; 359 (9314): 1269–75.
  21. Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21.
  22. Fischer M., Stedman M., Lii J. et al. Primary medication non-adherence: analysis of195,930 electronic prescriptions // J. Gen Intern. Med. – 2010; 25 (4): 284–90.
  23. Fihn S. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease // Circulation. – 2012; 126: e354–e471. https://doi.org/10.1161/CIR.0b013e318277d6a0
  24. Fox K., Garcia M., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: the task Force on the Management of stable Angina Pectoris of the European society of Cardiology // Eur. Heart J. – 2006; 27 (11): 1341–81.
  25. Horinaka S. Use of Nicorandil in Cardiovascular Disease and Its Optimization // Drugs. – 2011; 71 (9): 1105.
  26. Horinaka S., Yabe A., Yagi H. et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74: 503–9.
  27. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acutemyocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.
  28. Kasama S., Toyama T., Hatori T. et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy // Am. Heart J. – 2005; 150 (3): 477.
  29. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil // Cardiovasc. Drugs Ther. – 1990; 4 (4): 1075–88.
  30. Krumenacker M., Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy // J. Cardiovasc. Pharmacol. – 1992; 20 (Suppl. 3): 93–102.
  31. Lauer M., D’Agostino R. (Sr.). The randomized registry trial — the next disruptive technology in clinical research? // N. Engl. J. Med. – 2013; 369 (17): 1579–81.
  32. Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects // Drugs. – 2000; 60 (4): 955–74.
  33. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force of the European Society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003.
  34. Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. – 2004; 68 (3): 232–5.
  35. Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59 (1): 14–21.
  36. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
  37. Patel D., Purcell H., Fox K. On behalf of the CESAR 2 investigation. Cardioprotection by